Report Overview

The global gastrointestinal drugs market size stood at around USD 42 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The major factors that contribute to the growth of the gastrointestinal drugs market include the increasing prevalence of gastrointestinal diseases due to unhealthy dietary habits, additional numbers of clinical trials with accurate results, increasing healthcare expenditure, and growth in the geriatric population.



Market Drivers

According to the National Health Interview Survey (2017), 15.3 million adults were diagnosed with ulcers in the United States. Therefore a wide range of new generation drugs is found targeting that include novel small molecules and cellular therapy are currently under investigation. Other driving factors include the rising surgical treatments and hospitalizations, due to GI diseases, and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilar.

However, risk factors, such as those related to the physiological, behavioural, psychosocial, and socio-environmental aspects, restrict the populations from reporting the diseases early, which reflects the low awareness and the economic burden. These risk factors and the increasing number of patent expirations restrict the growth of the gastrointestinal drugs market.

Major Gastrointestinal Disease

Ulcerative Colitis is found to witness healthy CAGR over the forecast period. Ulcerative colitis is found to witness rapid growth in the gastrointestinal drugs market. The growth of this segment can be attributed to the easy availability of drugs in the market to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb the growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in a high probability of disease recurrence. In addition, Takeda Pharmaceuticals, Jassen Pharmaceuticals, and Pfizer are among the major global companies that have established themselves with their products for the treatment of inflammatory ulcerative colitis.